ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19 (EN/FR/NL)

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first patient has been treated in a Phase 1b/2 global clinical study of XVR011, its potent COVID-19 neutralizing antibody.

ExeVir announces first subjects dosed Phase 1 clinical study of potent COVID-19 neutralizing antibody (EN/FR/NL)

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.

ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments (EN/FR/NL)

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million.

ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern (EN/FR/NL)

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million.

ExeVir Announces Close of $50 million/ EUR42 million Series A Financing (EN/FR/NL)

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million.

ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection against SARS-COV-2 and related coronaviruses (EN/FR/NL)

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, announces publication in BioRxiv of a paper by VIB scientists showing, in in vivo mouse and hamster models, highly potent viral neutralizing activity, protection against infection by SARS-COV-2 and minimized development of alveolar [lung] damage, for XVR011, its unique Llama-derived VHH72-Fc antibody for potential treatment and prevention of Covid-19.

ExeVir Bio Appoints Michel Kazatchkine and Stef Heylen to the Board of Directors (EN/FR/NL)

ExeVir, which is developing nanobody therapies providing broad protection against viral infections, including a lead candidate for coronaviruses, today announced that Michel Kazatchkine and Stef Heylen have been appointed to the Board. Both strengthen ExeVir’s Board by adding pertinent R&D, in depth infectious disease and significant global health experience as ExeVir moves from preclinical to clinical with its lead candidate XVR011.

ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19 (EN/FR/NL)

ExeVir Bio announces today a first closing of a EUR23 million Series A financing led by Fund+, with the participation of VIB, UCB Ventures, the Belgian Federal Government via SFPI-FPIM, V-Bio Ventures and several Belgian family offices. ExeVir Bio has been established by Belgian partners combining world class science, antibody engineering, manufacturing, blue-chip venture capital investment and Flemish Government financing, which have joined forces in a unique collaboration to boost the development of new therapies to combat Covid-19